The ERS International Congress 2026 highlighted emerging evidence across severe asthma, allergic airway disease, pediatric wheeze, and cystic fibrosis, including real-world benefits of benralizumab in reducing exacerbations and systemic corticosteroid use, potential biomarker-guided omalizumab dose reduction , and real-world outcomes with sublingual versus subcutaneous allergen immunotherapy in children . 1-3 Additional research explored the association of allergic rhinitis with inflammatory and quality-of-life outcomes in asthma, the role of nasal IL-1β in habitual snoring among children with allergic rhinitis , and novel mechanisms targeting eosinophilic airway inflammation, including IL-33/SLC7A11-mediated disulfidptosis .

4-6 Explore this infographic for a concise overview of emerging evidence and clinical insights presented at ERS International Congress 2026. ##References##…